Analyst Price Target is $2.38
▲ +1,556.21% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $2.38, with a high forecast of $4.00 and a low forecast of $1.00. The average price target represents a 1,556.21% upside from the last price of $0.14.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Eloxx Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.